Viatris : VTRS Q1 2025 Earnings Infographic - FINAL

Published: 2025-05-08 07:07:11 ET VTRS

Published on 05/08/2025 at 07:07

Q1 2025

Financial Results

Total Revenues

$3.3B

Adjusted EBITDA*

$923M

Free Cash Flow*

Excluding Transaction Costs

$535M

Adjusted EPS*

$0.50

"2025 is off to a good start as we continue to focus on executing our strategic priorities. Our growing pipeline, capital discipline, operational execution, and significant global scope give us confidence in our ability to navigate the periods of increased volatility and uncertainty that our industry has been experiencing much of this year."

- Scott A. Smith

Chief Executive Officer

Delivering on Our 2025 Strategic Priorities

XULANE LO™

Fast-Acting Meloxicam (MR-107A-02)

Q1 operational performance in line with our expectations across all segments

Positive Phase 3 readouts for novel fast-acting meloxicam and XULANE LO™

Positive Phase 3 readout for EFFEXOR® for generalized anxiety disorder and filed sNDA in Japan

Selatogrel and cenerimod enrollment on track

Returned more than $450M of capital to shareholders YTD, including over $300M share repurchases and ~$143M dividends paid

Indore facility remediation on track and expect to submit request for reinspection mid-year

All primary and secondary endpoints met in both Phase 3 studies

In both studies, MR-107A-02 demonstrated statistically significant and clinically meaningful results

Targeting NDA submission to U.S. FDA by end of 2025

Achieved primary and all secondary efficacy and safety endpoints

Results demonstrated potential best-in-class patch performance

NDA submission to U.S. FDA anticipated in the second half of 2025

*Non-GAAP Financial Measure. For more information about Non-GAAP financial measures and reconciliations to the closest U.S. GAAP financial measure, as well as risks related to forward-looking statements, please read our

First Quarter 2025 Financial Results press release on our website.

Viatris.com LinkedIn @ViatrisInc @ViatrisInc YouTube Listen Well Podcast

© 2025 Viatris Inc. All Rights Reserved. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris Company.

Disclaimer

Viatris Inc. published this content on May 08, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 08, 2025 at 11:06 UTC.